Edesa Biotech Inc
Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. It develops EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome; and EB01, a topical vanishing cream containing non-… Read more
Edesa Biotech Inc (EDSA) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.142x
Based on the latest financial reports, Edesa Biotech Inc (EDSA) has a cash flow conversion efficiency ratio of -0.142x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.77 Million) by net assets ($12.45 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Edesa Biotech Inc - Cash Flow Conversion Efficiency Trend (2009–2025)
This chart illustrates how Edesa Biotech Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Edesa Biotech Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Edesa Biotech Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Dcon Products Public Company Limited
BK:DCON
|
0.001x |
|
ARSS Infrastructure Projects Limited
NSE:ARSSINFRA
|
-4.011x |
|
Skin n Skin Co. Ltd
KQ:159910
|
0.122x |
|
Manaksia Limited
NSE:MANAKSIA
|
-0.039x |
|
Linkhome Holdings Inc. Common stock
NASDAQ:LHAI
|
-0.431x |
|
PT Primadaya Plastisindo Tbk
JK:PDPP
|
0.027x |
|
Jasper Mining Corporation
PINK:JAMGF
|
-0.001x |
|
Chicago Rivet & Machine Co
NYSE MKT:CVR
|
0.032x |
Annual Cash Flow Conversion Efficiency for Edesa Biotech Inc (2009–2025)
The table below shows the annual cash flow conversion efficiency of Edesa Biotech Inc from 2009 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-09-30 | $12.32 Million | $-7.32 Million | -0.594x | +75.92% |
| 2024-09-30 | $1.98 Million | $-4.89 Million | -2.468x | -162.17% |
| 2023-09-30 | $7.05 Million | $-6.64 Million | -0.942x | +27.99% |
| 2022-09-30 | $9.39 Million | $-12.28 Million | -1.308x | -24.95% |
| 2021-09-30 | $13.06 Million | $-13.66 Million | -1.046x | -39.16% |
| 2020-09-30 | $6.63 Million | $-4.99 Million | -0.752x | +18.44% |
| 2019-09-30 | $5.26 Million | $-4.85 Million | -0.922x | -125.45% |
| 2018-09-30 | $11.29 Million | $-4.62 Million | -0.409x | +35.62% |
| 2017-09-30 | $7.40 Million | $-4.70 Million | -0.635x | -73.60% |
| 2016-09-30 | $12.31 Million | $-4.51 Million | -0.366x | +33.62% |
| 2015-09-30 | $8.01 Million | $-4.41 Million | -0.551x | +0.52% |
| 2014-09-30 | $7.70 Million | $-4.27 Million | -0.554x | -159.51% |
| 2013-09-30 | $-3.14 Million | $-2.92 Million | 0.931x | +120.08% |
| 2012-09-30 | $851.61K | $-3.95 Million | -4.636x | -713.47% |
| 2011-09-30 | $4.59 Million | $-2.62 Million | -0.570x | -92.42% |
| 2010-09-30 | $2.47 Million | $-732.23K | -0.296x | -281.29% |
| 2009-09-30 | $484.95K | $-37.67K | -0.078x | -- |